Clinical Trial Update: Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Bomedemstat (IMG-7289/MK-3543) in myelofibrosis showing completion and posted results for Phase 1/2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Conditions: Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-10